Holen Sie sich die Stockscreener-App
1.12
2.61%
-0.03
Handel nachbörslich:
1.06
-0.06
-5.36%
Schlusskurs vom Vortag:
$1.15
Offen:
$1.2
24-Stunden-Volumen:
888.35K
Relative Volume:
2.39
Marktkapitalisierung:
$41.05M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.16M
KGV:
-1.9649
EPS:
-0.57
Netto-Cashflow:
$-8.75M
1W Leistung:
+34.10%
1M Leistung:
+16.67%
6M Leistung:
-14.83%
1J Leistung:
-15.15%
1-Tages-Spanne:
$1.09
$1.25
1-Wochen-Bereich:
$0.87
$1.25
52-Wochen-Spanne:
$0.7006
$1.6899
Renovorx Inc Stock (RNXT) Company Profile
Firmenname
Renovorx Inc
Sektor
Branche
Telefon
408-800-2649
Adresse
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Vergleichen Sie RNXT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
1.12 | 42.15M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Renovorx Inc Aktie (RNXT) Neueste Nachrichten
RenovoRx, Inc. (RNXT) Reports Q3 Loss, Lags Revenue Estimates - MSN
Will RenovoRx Inc. stock deliver better than expected guidanceJuly 2025 Setups & Long-Term Capital Growth Strategies - ulpravda.ru
RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026 - Sahm
Will RenovoRx Inc. stock reach all time highs in 20252025 Market Outlook & Low Risk High Win Rate Picks - ulpravda.ru
Is RenovoRx Inc. stock resilient to inflationJuly 2025 Momentum & Capital Protection Trade Alerts - ulpravda.ru
How sustainable is RenovoRx Inc. stock dividend payout2025 Risk Factors & Weekly High Potential Stock Alerts - ulpravda.ru
Investor Mood: Will RenovoRx Inc stock see PE expansionMarket Sentiment Report & Real-Time Buy Zone Alerts - moha.gov.vn
Can RenovoRx Inc. stock continue upward trendTrade Risk Assessment & Growth Focused Stock Pick Reports - ulpravda.ru
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech - St. Catharines Standard
Will RenovoRx Inc. stock see PE expansionShort Setup & Free Weekly Chart Analysis and Trade Guides - ulpravda.ru
RenovoRx To Announce Promising New Clinical Data Using its TAMP Therapy Platform in an Abstract to be Presented at ASCO GI 2026 - Investing News Network
New study aims to make pancreatic cancer chemo hit tumors, not the whole body - Stock Titan
RenovoRx (NASDAQ:RNXT) Stock Price Down 1% – Here’s Why - Defense World
Will RenovoRx Inc. stock pay special dividends2026 world cup usa national team quarterfinals defensive leaders high defensive line knockout prediction expert opinion - ulpravda.ru
RenovoRx receives Nasdaq notice for bid price noncompliance - MSN
RenovoRx Receives Nasdaq Notice for Bid Price Noncompliance - TipRanks
RenovoRx Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
Aug Opening: How RenovoRx Inc stock responds to policy changesQuarterly Profit Summary & Smart Swing Trading Techniques - moha.gov.vn
Shaun Bagai buys RenovoRx (RNXT) shares worth $4506 By Investing.com - Investing.com Australia
Shaun Bagai buys RenovoRx (RNXT) shares worth $4506 - Investing.com India
Friday's After-Hours Gainers: Biotech And Genomics Stocks Show Strength - Nasdaq
Is RenovoRx Inc. stock attractive for growth ETFsJuly 2025 Setups & Free Long-Term Investment Growth Plans - Улправда
RenovoRx's Differentiated Targeted Drug Delivery Platform Addresses Hypovascular Cancers - Smartkarma
How RenovoRx Inc. stock performs during Fed tightening cyclesIndex Update & Safe Capital Growth Stock Tips - Улправда
How RenovoRx Inc. stock reacts to inflationary pressuresJuly 2025 Intraday Action & Weekly Setup with ROI Potential - Улправда
How RenovoRx Inc. stock responds to policy changesJuly 2025 Retail & Capital Efficient Trade Techniques - DonanımHaber
CEO Bagai Buys 5,000 ($4.3K) Of RenovoRx Inc [RNXT] - TradingView — Track All Markets
Why RenovoRx Inc. stock could outperform in 2025Trade Risk Report & Short-Term High Return Strategies - DonanımHaber
RenovoRx Earnings Notes - Trefis
RenovoRx Executive Makes a Significant Stock Purchase! - TipRanks
Chmn Agah Buys 12,000 ($10.2K) Of RenovoRx Inc [RNXT] - TradingView — Track All Markets
RenovoRx CMO Ramtin Agah Buys 12,000 Shares - TradingView — Track All Markets
RenovoRx, Inc. (RNXT) CMO-director purchases 12,000 shares at $0.85 - Stock Titan
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026 - Investing News Network
RenovoRx Announces Acceptance of Abstract for Presentation at ASCO GI 2026 on Innovative Targeted Therapy for Pancreatic Cancer - Quiver Quantitative
RenovoRx (Nasdaq: RNXT) to Present TIGeR-PaC PK/PD Data at ASCO GI Symposium 2026 - Stock Titan
Transcript : RenovoRx, Inc. Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025, Dec-09-2025 through Dec-10-2025 - marketscreener.com
RNXT: Six-month survival benefit and strong early revenue position the company for growth in 2026 - TradingView — Track All Markets
Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025 - Investing News Network
Agah Ramtin, RenovoRx chief medical officer, buys $9,600 in RNXT - Investing.com
Is RenovoRx Inc. stock near bottom after declineJuly 2025 Chart Watch & Precise Entry and Exit Recommendations - Newser
What makes RenovoRx Inc. stock attractive to growth funds2025 Momentum Check & Weekly Chart Analysis and Guides - Newser
RenovoRx (RNXT) Stock Analysis Report | Financials & Insights - Benzinga
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th - Investing News Network
RenovoRx CEO to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 - Quiver Quantitative
RenovoRx (Nasdaq: RNXT) CEO to detail RenovoCath updates at iAccess Alpha - Stock Titan
RenovoRx files $50M mixed securities shelf - MSN
Big Money Moves: Is RenovoRx Inc. stock attractive for growth ETFsMarket Trend Review & Safe Entry Zone Tips - BỘ NỘI VỤ
RenovoRx CMO Makes Bold Stock Purchase - TipRanks
[Form 4] RenovoRx, Inc. Insider Trading Activity - Stock Titan
RenovoRx CMO Ramtin Agah Acquires 22,000 Shares - TradingView
Finanzdaten der Renovorx Inc-Aktie (RNXT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Renovorx Inc-Aktie (RNXT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Agah Ramtin | Chief Medical Officer |
Dec 30 '25 |
Buy |
0.83 |
205 |
169 |
778,665 |
| Bagai Shaun | Chief Executive Officer |
Dec 18 '25 |
Buy |
0.90 |
5,000 |
4,506 |
340,040 |
| Bagai Shaun | Chief Executive Officer |
Dec 17 '25 |
Buy |
0.85 |
5,000 |
4,262 |
335,040 |
| Agah Ramtin | Chief Medical Officer |
Dec 16 '25 |
Buy |
0.85 |
12,000 |
10,200 |
778,460 |
| Agah Ramtin | Chief Medical Officer |
Dec 05 '25 |
Buy |
0.96 |
10,000 |
9,600 |
766,460 |
| Agah Ramtin | Chief Medical Officer |
Nov 24 '25 |
Buy |
0.80 |
12,000 |
9,600 |
756,460 |
| Agah Ramtin | Chief Medical Officer |
Nov 21 '25 |
Buy |
0.80 |
10,000 |
8,000 |
744,460 |
| Bagai Shaun | Chief Executive Officer |
Aug 22 '25 |
Buy |
0.95 |
5,000 |
4,748 |
325,040 |
| Bagai Shaun | Chief Executive Officer |
Aug 25 '25 |
Buy |
0.91 |
5,000 |
4,549 |
330,040 |
| Agah Ramtin | Chief Medical Officer |
Jun 05 '25 |
Buy |
1.40 |
21,000 |
29,400 |
734,460 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):